MeadowBrook Investment Advisors LLC Sells 3,797 Shares of CVS Health Co. (NYSE:CVS)

MeadowBrook Investment Advisors LLC lessened its position in shares of CVS Health Co. (NYSE:CVS) by 26.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,814 shares of the pharmacy operator’s stock after selling 3,797 shares during the quarter. MeadowBrook Investment Advisors LLC’s holdings in CVS Health were worth $485,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. MidAtlantic Capital Management Inc. acquired a new stake in shares of CVS Health during the 3rd quarter worth approximately $25,000. Livelsberger Financial Advisory acquired a new stake in CVS Health in the 3rd quarter valued at $31,000. Legacy Investment Solutions LLC bought a new position in CVS Health in the 3rd quarter valued at $31,000. Reston Wealth Management LLC bought a new position in CVS Health in the 3rd quarter valued at $32,000. Finally, Ridgewood Investments LLC raised its position in CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 450 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analysts Set New Price Targets

CVS has been the subject of several research analyst reports. UBS Group cut their price objective on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research report on Tuesday. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Tuesday, December 3rd. Piper Sandler dropped their target price on CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research report on Monday, November 25th. Wolfe Research upped their price objective on CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Edward Jones upgraded CVS Health from a “hold” rating to a “buy” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $67.78.

CVS Health Price Performance

NYSE:CVS opened at $55.01 on Wednesday. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The stock’s 50 day moving average price is $50.69 and its two-hundred day moving average price is $55.95. The firm has a market capitalization of $69.23 billion, a price-to-earnings ratio of 13.96, a P/E/G ratio of 0.60 and a beta of 0.61. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $80.75.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 4.84%. The ex-dividend date was Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is 67.51%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.